{
  "id": "9bd478c6c05292cf",
  "title": "Biodexa Licenses Phase 1 - Ready Drug Candidate From Otsuka For Rare Stomach Cancer - Biodexa Pharmaceuticals ( NASDAQ : BDRX ), Cogent Biosciences ( NASDAQ : COGT ) ",
  "description": "20260219T134500Z",
  "content": "",
  "source": "benzinga.com",
  "source_url": "https://www.benzinga.com/partner/equities/26/02/50713477/biodexa-licenses-phase-1-ready-drug-candidate-from-otsuka-for-rare-stomach-cancer",
  "published_at": "20260219T134500Z",
  "fetched_at": "2026-02-20T00:27:32.210173+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "drug"
  ],
  "location": "United States",
  "raw_data": {
    "url": "https://www.benzinga.com/partner/equities/26/02/50713477/biodexa-licenses-phase-1-ready-drug-candidate-from-otsuka-for-rare-stomach-cancer",
    "url_mobile": "",
    "title": "Biodexa Licenses Phase 1 - Ready Drug Candidate From Otsuka For Rare Stomach Cancer - Biodexa Pharmaceuticals ( NASDAQ : BDRX ), Cogent Biosciences ( NASDAQ : COGT ) ",
    "seendate": "20260219T134500Z",
    "socialimage": "https://cdn.benzinga.com/files/images/story/2026/02/19/Untitled-design-22.png?&fit=crop",
    "domain": "benzinga.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}